Modulation of opioid actions by nitric oxide signaling

Anesthesiology

Volumn 110, Issue 1, 2009, Pages 166-181

  Toda, Noboru ^a,b   Kishioka, Shiroh ^c   Hatano, Yoshio ^c   Toda, Hiroshi ^b,d  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^b Toyama Institute for Cardiovascular Pharmacology Research   (Japan)

^c WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^d KYOTO KATSURA HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 ETHYL 2 HYDROXYIMINO 5 NITRO 3 HEXENAMIDE; ALPHA 2 ADRENERGIC RECEPTOR; CODEINE; CYCLIC GMP; DEXTROPROPOXYPHENE PLUS PARACETAMOL; DICLOFENAC; DIPYRONE; DIZOCILPINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLYCERYL TRINITRATE; INDUCIBLE NITRIC OXIDE SYNTHASE; KETAMINE; MORPHINE; MU OPIATE RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NARCOTIC ANALGESIC AGENT; NEURONAL NITRIC OXIDE SYNTHASE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PLACEBO; POTASSIUM CHANNEL; SILDENAFIL;

ANALGESIC ACTIVITY; ANTINOCICEPTION; CANCER PAIN; DOG; ENDOTHELIUM; ENZYME INHIBITION; GLIA CELL; HUMAN; MITOCHONDRION; MORPHINE ADDICTION; MORPHINE TOLERANCE; MOUSE; NERVE CELL; NEUROPATHIC PAIN; NONHUMAN; OXIDATIVE STRESS; PAIN THRESHOLD; POSTOPERATIVE ANALGESIA; POSTOPERATIVE PAIN; PRESSOR RESPONSE; PRIORITY JOURNAL; RAT; REVIEW; SIGNAL TRANSDUCTION; SYNTHESIS; TAIL FLICK TEST; WITHDRAWAL SYNDROME; ANIMAL; DRUG EFFECT; METHODOLOGY; PAIN ASSESSMENT; PHYSIOLOGY;

ANALGESICS, OPIOID; ANIMALS; HUMANS; NITRIC OXIDE; PAIN MEASUREMENT; PAIN THRESHOLD; SIGNAL TRANSDUCTION;

EID: 58749107193     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0b013e31819146a9     Document Type: Review

References (164)

1. Furchgott RF, Zawadzki JV: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature (Lond) 1980; 288:373-6
2. Furchgott RF: Studies on relaxation of rabbit aorta by sodium nitrite: The basis for the proposal that the acid-activatable inhibitory factor from bovine retractor penis is inorganic nitrite and the endothelium-derived relaxing factor is nitric oxide, Vasodilatation: Vascular Smooth Muscle, Autonomic Nerves, and Endothelium. Edited by Vanhoutte PM, New York, Raven Press, 1988, pp. 401-14
3. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G: Endotheliumderived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A 1987; 84:9265-9
4. Palmer RM, Ferrige AB, Moncada S: Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature (Lond) 1987; 327:524-6
5. Bredt DS, Snyder GH: Isolation of nitric oxide synthetase, a calmodulinrequiring enzyme. Proc Natl Acad Sci U S A 1990; 87:682-5
6. Hebel JM, White KA, Marletta MA: Purification of the inducible murine macrophage nitric oxide synthase: identification as a flavo-protein. J Biol Chem 1991; 266:22789-91
7. Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, MuirheadG, Naylor AM, Osterloch IH, Gengell C: Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 1996; 8:47-52
8. Toda N, Ayajiki K, Okamura T: Nitric oxide and penile erectile function. Pharmacol Ther 2005; 106:233-66
9. Toda N, Toda H, Hatano Y: Nitric oxide: Involvement in the effects of anesthetic agents. ANESTHESIOLOGY 2007; 107:822-42
10. Förstermann U, Pollock JS, Schmidt HH, Heller M, Murad F: Calmodulindependent endothelium-derived relaxing factor/nitric oxide synthase activity is present in the particulate and cytosolic fractions of bovine aortic endothelial cells. Proc Nat Acad Sci U S A 1991; 88:1788-92
11. Palmer RMJ, Rees DD, Ashton DS, Moncada S: L-Arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem Biophys Res Commun 1988; 153:1251-6
12. Rees DD, Palmer RMJ, Schulz R, Hodson HF, Moncada S: Characterization of three inhibitors of endothelial nitric oxide synthase in vivo and in vitro. Br J Pharmacol 1990; 101:746-52
13. Toda N, Minami Y, Okamura T: Inhibitory effects of L-NG-nitro-arginine on the synthesis of EDRF and the cerebroarterial response to vasodilator nerve stimulation. Life Sci 1990; 47:345-51
14. Vallance P, Leone A, Calver A, Collier J, Moncada S: Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J Cardiovasc Pharmacol 1992; 20(Suppl12):S60-2
15. Moore PK, Babbedge RC, Wallace P, Gaffen ZA, Hart SL: 7-Nitroindazole, an inhibitor of nitric oxide synthase, exhibits antinociceptive activity in the mouse without increasing blood pressure. Br J Pharmacol 1993; 108:296-7
16. Griffiths MJ, Messent M, MacAllister RJ, Evans TW: Aminoguanidine selectively inhibits inducible nitric oxide synthase. Br J Pharmacol 1993; 110:963-8
17. Garthwaite J, Southam E, Boulton CL, Nielsen EB, Schmidt K, Mayer B: Potential and selective inhibition of nitric oxide sensitive guanylate cyclase by 1H[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-on. Mol Pharmacol 1995; 48:184-8
18. Mixcoatl-Zecuatl T, Flores-Murrieta FJ, Granados-Soto V: The nitric oxidecyclic GMP-protein kinase G-K- channel pathway participates in the antiallodynic effect of spinal gabapentin. Eur J Pharmacol 2006; 531:87-95
19. Brito GA, Sachs D, Cunha FQ, Vale ML, Lotufo CM, Ferreira SH, Ribeiro RA: Peripheral antinociceptive effect of pertussis toxin: activation of the arginine/NO/ cGMP/PKG/ATP-sensitive K channel pathway. Eur J Neurosci 2006; 24:1175-81
20. Oritz MI, Medina-Tat DA, Sarmiento-Heredia D, Palma-Martinez J, Ganados- Soto V: Possible activation of the NO-cyclic GMP-protein kinase G-K- channels pathway by gabapentin on the formalin test. Pharmacol Biochem Behav 2006; 83:420-7
21. Scavone C, Munhoz CD, Kawamoto EM, Glezer I, de Sa Lima L, Marcourakis T, Markus RP: Age-related changes in cyclic GMP and PKG-stimulated cerebellar Na,K-ATPase activity. Neurobiol Aging 2005; 26:907-16
22. Ramamoorthy S, Samuvel DJ, Buck ER, Rudnick G, Jayanthi LD: Phosphorylation of threonine residue 276 is required for acute regulation of serotonin transporter by cyclic GMP. J Biol Chem 2007; 282:11639-47
23. Zhang YW, Gesmonde J, Ramamoorthy S, Rudnick G: Serotonin transporter phosphorylation by cGMP-dependent protein kinase is altered by a mutation associated with obsessive compulsive disorder. J Neurosci 2007; 27:10878-86
24. Toda N, Okamura T: Possible role of nitric oxide in transmitting information from vasodilator nerve to cerebral arterial muscle. Biochem Biophys Res Commun 1990; 170:308-13
25. Zheng Z, Shimamura K, Anthony TL, Travagli RA, Kreulen DL: Nitric oxide is a sensory nerve neurotransmitter in the mesenteric artery of guinea pig. J Auton Nerv Syst 1997; 29:137-44
26. Zochodne DW, Levy D: Nitric oxide in damage, disease and repair of the peripheral nervous system. Cell Mol Biol 2005; 51:255-67
27. Holzer P: Efferent-like roles of afferent neurons in the gut: blood flow regulation and tissue protection. Auton Neurosci 2006; 125:70-5
28. Kiss JP, Vizi ES: Nitric oxide: a novel link between synaptic and nonsynaptic transmission. Trends Neurosci 2001; 24:211-5
29. Riedel W, Neeck G: Nociception, pain, and antinociception: current concepts. Z Rheumatol 2001; 60:404-15
30. Levy D, Zochodne DW: NO pain: potential roles of nitric oxide in neuropathic pain. Pain Pract 2004; 4:11-8
31. Bargaud JL, Riffaud JP, Del Soldato P: Nitric-oxide releasing molecules: a new class of drugs with several major indications. Curr Pharm Des 2002; 8:201-13
32. Romero-Sandoval EA, Curros-Criado MM, Gaitan G, Molina Herrero JF: Nitroparacetamol (NCX-701) and pain: first in a series of novel analgesics. CNS Drug Rev 2007; 13:279-95
33. Leza JC, Lizasoain I, San-Martin-Clark O, Lorenzo P: Morphine-induced changes in cerebral and cerebellar nitric oxide synthase activity. Eur J Pharmacol 1995; 285:95-8
34. Machelska H, Ziolkowska B, Mika J, Prezewlocka B, Prezewlocki R: Chronic morphine increases biosynthesis of nitric oxide synthase in the rat spinal cord. Neuroreport 1997; 8:2743-7
35. Kumar S, Bhargava HN: Time course of the changes in central nitric oxide synthase activity following chronic treatment with morphine in the mouse: reversal by naltrexone. Gen Pharmacol 1997; 223-7
36. Nieto-Fernandez FE, Mattocks D, Cavani F, Salzet M, Stefano GB: Morphine coupling to invertebrate immunocyte nitric oxide release is dependent on intracellular calcium transients. Comp Biochem Physiol B Biochem Mol Biol 1999; 123: 295-9
37. Yoo JH, Cho JH, Lee SY, Lee S, Loh HH, Ho IK, Jang CG: Differential effects of morphine- and cocaine-induced nNOS immunoreactivity in the dentate gyrus of hippocampus of mice lacking -opioid receptors. Neurosci Lett 2006; 395: 98-102
38. Barjavel MJ, Bhargava HN: Effect of opioid receptor agonists on nitric oxide synthase activity in rat cerebral cortex homogenate. Neurosci Lett 1994; 181:27-30
39. Babey AM, Kolesnikov Y, Cheng J, Inturrisi CE, Trifilletti RR, Pasternak GW: Nitric oxide and opioid tolerance. Neuropharmacology 1994; 33:1463-70
40. Dyuizen IV, Motavkin PA, Shorin VV: Dynamics of NADPH diaphorase activity in raphe neurons during chronic treatment with opiates. Bull Exp Biol Med 2001; 132:918-20
41. Dyuizen IV, Deridovich II, Kurbatskii RA, Shorin VV: NO-ergic neurons of the cervical nucleus of the rat brain in normal conditions and after administration of opiates. Neurosci Behav Physiol 2004; 34:621-6
42. Stefano GB, Hartman A, Bilfinger TV, Magazine HI, Liu Y, Casares F, Goligorsky MS: Presence of the -3 opiate receptor in endothelial cells. Coupling to nitric oxide production and vasodilation. J Biol Chem 1995; 270:30290-3
43. Stefano GB, Salzet M, Bilfinger TV: Long-term exposure of human blood vessels to HIV gp120, morphine, and anandamide increases endothelial adhesion of monocytes: uncoupling of nitric oxide release. J Cardiovac Pharmacol 1998; 31:862-9
44. Xu Z, Tong C, Pan HL, Cerda SE, Eisenach JC: Intravenous morphine increases release of nitric oxide from spinal cord by an a-adrenergic and cholinergic mechanism. J Neurophysiol 1997; 78:2072-8
45. Fimiani C, Arcuri E, Santoni A, Rialas CM, Bilfinger TV, Peter D, Salzet B, Stefano GB: -3 Opiate receptor expression in lung and lung carcinoma: ligand binding and coupling to nitric oxide release. Cancer Lett 1999; 146:45-51
46. Zhu W, Ma Y, Bell A, Esch T, Guarna M, Bilfinger TV, Bianchi E, Stefano GB: Presence of morphine in rat amygdala: evidence for the -3 opiate receptor subtypes via nitric oxide release in limbic structures. Med Sci Monit 2004; 10:BR433-9
47. Tseng L, Mazella J, Goligorsky MS, Rialas CM, Stefano GB: Dopamine and morphine stimulate nitric oxide release in human endometrial glandular epithelial cells. J Soc Gynecol Investig 2000; 7:343-7
48. Saric' A, Balog T, Sobocanec S, Marotti T: Endomorphine 1 activates nitric oxide synthase 2 activity and downregulates nitric oxide synthase 2 mRNA expression. Neuroscience 2007; 144:1454-61
49. Kielstein A, Tsikas D, Galloway GP, Mendelson JE: Asymmetric dimethylarginine (ADMA)-a modulator of nociception in opiate tolerance and addiction? Nitric Oxide 2007; 17:55-9
50. Pu S, Horvath TL, Diano S, Naftolin F, Kalra PS, Kalra SP: Evidence showing that -endorphin regulates cyclic guanosine 3=,5=-monophosphate (cGMP) efflux: anatomical and functional support for an interaction between opiates and nitric oxide. Endocrinology 1997; 138:1537-43
51. Ferreira SH, Duarte ID, Lorenzetti BB: Molecular base of acetylcholine and morphine analgesia. Agents Actions Supple 1991; 32:101-6
52. Duarte ID, Ferreira SH: The molecular mechanism of central analgesia induced by morphine or carbachol and the L-arginine-nitric oxide-cGMP pathway. Eur J Pharmacol 1992; 221:171-4
53. Xu JY, Tseng LF: Role of nitric oxide/cyclic GMP in i.c.v. administrated -endorphin- and (-)-cis-dioxolane-induced antinociception in the mouse. Eur J Pharmacol 1994; 262:223-31
54. Pataki I, Telegdy G: Further evidence that nitric oxide modifies acute and chronic morphine actions in mice. Eur J Pharmacol 1998; 357:157-62
55. Chung E, Burke B, Bieber AJ, Doss JC, Ohgami Y, Quock RM: Dynorphinmediated antinociceptive effects of L-arginine and SIN-1 (an NO donor) in mice. Brain Res Bull 2006; 70:245-50
56. Javanmardi K, Parviz M, Sadr SS, Keshavarz M, Minaii B, Dehpour AR: Involvement of N-methyl-D-aspartate receptors and nitric oxide in the rostral ventromedial medulla in modulating morphine pain-inhibitory signals from the periaqueductal grey matter in rats. Clin Exp Pharmacol Physiol 2005; 32:585-9
57. Moore PK, Oluyomi AO, Babbedge RC, Wallace P, Hart SL: L-NG-nitro arginine methyl ester exhibits antinociceptive activity in the mouse. Br J Pharmacol 1991; 102:198-202
58. Pelligrino DA, Laurito CE, VadeBoncouer TR: Nitric oxide synthase inhibition modulates the ventilatory depression and antinociceptive actions of fourth ventricular infusions of morphine in the awake dog. ANESTHESIOLOGY 1996; 85:1367-77
59. Bhargava HN, Bian JT: Effects of acute and chronic administration of L-arginine on the antinociceptive action of morphine-6-D-glucuronide. Pharmacology 1997; 55:165-72
60. Bhargava HN, Bian JT: NG-nitro-L-arginine reversed L-arginine induced changes in morphine antinociception and distribution of morphine in brain regions and spinal cord of the mouse. Brain Res 1997; 749:351-3
61. Bian JT, Bhargava HN: Effect of chronic administration of L-arginine, NG-nitro-L-arginine or their combination on morphine concentration in peripheral and urine of the mouse. Gen Pharmacol 1998; 30:753-7
62. Bhargava HN, Bian JT, Kumar S: Mechanism of attenuation of morphine antinociception by chronic treatment with L-arginine. J Pharmacol Exp Ther 1997; 281:707-12
63. Bhargava HN, Bian JT: Effects of acute administration of L-arginine on morphine antinociception and morphine distribution in central and peripheral tissues of mice. Pharmacol Biochem Behav 1998; 61:29-33
64. Grover VS, Sharma A, Singh M: Role of nitric oxide in diabetes-induced attenuation of antinociceptive effect of morphine in mice. Eur J Pharmacol 2000; 399:161-4
65. Terenghi G, Riveros-Moreno V, Hudson LD, Ibrahim NB, Polak JM: Immunohistochemistry of nitric oxide synthase demonstrates immunoreactive neurons in spinal cord and dorsal ganglia of man and rat. J Neurol Sci 1993; 118:34-7
66. Kolesnikov YA, Pan YX, Babey AM, Jain S, Wilson R, Pasternak GW: Functionally differentiating two neuronal nitric oxide synthase isoforms through antisense mapping: evidence for opposing NO actions on morphine analgesia and tolerance. Proc Natl Acad Sci U S A 1997; 94:8220-5
67. Song HK, Pan HL, Eisenach JC: Spinal nitric oxide mediates antinociception from intravenous morphine. ANESTHESIOLOGY 1998; 89:215-21
68. Hayashida K, Takeuchi T, Shimizu H, Ando K, Harada E: Lactoferrin enhances opioid-mediated analgesia via nitric oxide in the rat spinal cord. Am J Physiol 2003; 285:R302-5
69. Chen SR, Pan HL: Spinal nitric oxide contributes to the analgesic effect of intrathecal [d-pen2,d-pen5]-enkephalin in normal and diabetic rats. ANESTHESIOLOGY 2003; 98:217-22
70. Yamaguchi H, Naito H: Antinociceptive synergistic interaction between morphine and N-nitro-L-arginine methyl ester on thermal nociceptive tests in the rats. Can J Anaesth 1996; 43:975-81
71. Przewlocki R, Machelska H, Przewlocka B: Inhibition of nitric oxide synthase enhances morphine antinociception in the rat spinal cord. Life Sci 1993; 53:PL1-5
72. Machelska H, Labuz D, Prezewlocki R, Prezewlocka B: Inhibition of nitric oxide synthase enhances antinociception mediated by mu, delta, and kappa opioid receptors in acute and prolonged pain in the rat spinal cord. J Pharmacol Exp Ther 1997; 282:977-84
73. Li X, Clark JD: Spinal cord nitric oxide synthase and heme oxygenase limit morphine induced analgesia. Mol Brain Res 2001; 95:96-102
74. Watanabe C, Sakurada T, Okuda K, Sakurada C, Ando R, Sakurada S: The role of spinal nitric oxide and glutamate in nociceptive behaviour evoked by high-dose intrathecal morphine in rats. Pain 2003; 106:269-83
75. Watanabe C, Okuda K, Sakurada C, Ando R, Sakurada T, Sakurada S: Evidence that nitric oxide-glutamate cascade modulates spinal antinociceptive effect of morphine: a behavioural and microdialysis study in rats. Brain Res 2003; 990:77-86
76. Durate ID, Lorenzetti BB, Ferreira SH: Peripheral analgesia and activation of the nitric oxide-cyclic GMP pathway. Eur J Pharmacol 1990; 186:289-93
77. Ferreira SH, Duarte ID, Lorenzetti BB: The molecular mechanism of action of peripheral morphine analgesia: stimulation of the cGMP system via nitric oxide release. Eur J Pharmacol 1991b; 201:121-2
78. Granados-Soto V, Rufino MO, Gomes Lopes LD, Ferreira SH: Evidence for the involvement of the nitric oxide-cGMP pathway in the antinociception of morphine in the formalin test. Eur J Pharmacol 1997; 340:177-80
79. Nozaki-Taguchi N, Yamamoto T: The interaction of FK409, a novel nitric oxide releaser, and peripherally administered morphine during experimental inflammation. Anesth Analg 1998; 86:367-73
80. Aquirre-Banuelos P, Granados-Soto V: Evidence for a peripheral mechanism of action for the potentiation of the antinociceptive effect of morphine by dipyrone. J Pharmacol Toxicol Methods 1999; 42:79-85
81. Mixcoatl-Zecuatl T, Aguirre-Banuelos P, Granadoes-Soto V: Sildenafil produces antinociception and increases morphine antinociception in the formalin test. Eur J Pharmacol 2000; 400:81-7
82. Jain NK, Patil CS, Singh A, Kulkarni SK: Sildenafil, a phosphodiesterase5 inhibitor, enhances the antinociceptive effect of morphine. Pharmacology 2003; 67:150-6
83. Hayashida K, Takeuchi T, Harada E: Lactoferrin enhances peripheral opioid- mediated antinociception via nitric oxide in rats. Eur J Pharmacol 2004; 484:175-81
84. Oritz MI, Castro-Olguin J, Pena-Samaniego N, Castaneda-Hernandez G: Probable activation of the opioid receptor-nitric oxide-cyclic GMP-K- channels pathway by codeine. Pharmacol Biochem Behav 2005; 82:695-703
85. Stanojevic S, Mitic K, Vujic V, Kovacevic-Jovanovid V, Dimitrijevic M: Beta-endorphine differentially affects inflammation in two inbred rat strains. Eur J Pharmacol 2006; 549:157-65
86. Okun R, Liddon SC, Lasagnal L: The effects of aggregation, electric shock, and adrenergic blocking drug on inhibition of the "writhing syndrome." J Pharmacol Exp Ther 1963; 139:107-9
87. Abacioglu N, Ozmen R, Cakici I, Tunctan B, Kanzik I: Role of L-arginine/ nitric oxide pathway in the antinociceptive activities of morphine and mepyramine in mice. Arzneimittelforschung 2001; 51:977-83
88. Homayoun H, Khavandgar S, Dehpour AR: The selective role of nitric oxide in opioid-mediated foodshock stress antinociception in mice. Physiol Behav 2003; 79:567-73
89. Brignola G, Calignano A, Di Rosa M: Modulation of morphine antinociception in the mouse by endogenous nitric oxide. Br J Pharmacol 1994; 113:1372-6
90. Guney HZ, Gorgun CZ, Tunctan B, Uludag O, Hodoglugil U, Abacioglu N, Zengil H: Circadian-rhythm-dependent effects of L-NG-nitroarginine methyl ester (L-NAME) on morphine-induced analgesia. Chronobiol Int 1998; 15:283-9
91. Dixon SJ, Persinger MA: Suppression of analgesia in rats induced by morphine or L-NAME but not both drugs by micro Tesla, frequency-modulated magnetic fields. Int J Neurosci 2001; 108:87-97
92. Homayoun H, Khavandgar S, Namiranian K, Dehpour AR: The effect of cyclosporine A on morphine tolerance and dependence: involvement of L-arginine/nitric oxide pathway. Eur J Pharmacol 2002; 452:67-75
93. Ozek M, Uresin Y, Gungor M: Comparison of the effects of specific and nonspecific inhibition of nitric oxide synthase on morphine analgesia, tolerance and dependence in mice. Life Sci 2003; 72:1943-51
94. Khattab MM, El-Hadiyah TM, Al-Shabanah OA, Raza M: Modification by L-NAME of codeine induced analgesia: possible role of nitric oxide. Receptors Channels 2004; 10:139-45
95. Singal A, Anjaneyulu M, Chopra K: Modulatory role of green tea extract on antinociceptive effect of morphine in diabetic mice. J Med Food 2005; 8:386-91
96. Altug S, Uludag O, Tunctan B, Cakici I, Zengil H, Abacioglu N: Biological time-dependent difference in effect of peroxynitrite demonstrated by the mouse hot plate pain model. Chronobiol Int 2006; 23:583-91
97. Lauretti GR, Lima IC, Reis MP, Prado WA, Pereira NL: Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management. ANESTHESIOLOGY 1999; 90:1528-33
98. Lauretti GR, Perez MV, Reis MP, Pereira NL: Double-blind evaluation of transdermal nitroglycerine as adjuvant to oral morphine for cancer pain management. J Clin Anesth 2002; 14:83-6
99. Iohom G, Abdalla H, O'Brien J, Szarvas S, Larney V, Buckley E, Butler M, Shorten GD: The associations between severity of early postoperative pain, chronic postsurgical pain and plasma concentration of stable nitric oxide products after breast surgery. Anesth Analg 2006; 103:995-1000
100. Sousa AM, Prado WA: The dual effect of a nitric oxide donor in nociception. Brain Res 2001; 897:9-19
101. Kolesnikov YA, Pick CG, Pasternak GW: NG-nitro-L-arginine prevents morphine tolerance. Eur J Pharmacol 1992; 221:399-400
102. Elliott K, Minami N, Kolesnikov YA, Pasternak GW, Inturrisi CE: The NMDA receptor antagonists, LY274614 and MK-804, and the nitric oxide synthase inhibitor, NG-nitro-L-arginine, attenuate analgesic tolerance to the -opioid morphine but not to - opioids. Pain 1994; 56:69-75
103. Majeed NH, Przewlocka B, Machelska H, Przewlocki R: Inhibition of nitric oxide synthase attenuates the development of morphine tolerance and dependence in mice. Neuropharmacology 1994; 33:189-92
104. Highfield DA, Grant S: NG-nitro-L-arginine, an NOS inhibitor, reduces tolerance to morphine in the rat locus coeruleus. Synapse 1998; 29:233-9
105. Homayoun H, Khavandgar S, Namiranian K, Dehpour AR: The effect of cyclosporine A on morphine tolerance and dependence: involvement of Larginine/ nitric oxide pathway. Eur J Pharmacol 2002; 452:67-75
106. Kolesnikov YA, Pick CG, Ciszewska G, Pasternak GW: Blockade of tolerance but not to - opioids by a nitric oxide synthase inhibitor. Proc Natl Acad Sci USA 1993; 90:5162-6
107. Bhargava HN, Zhao GM: Effect of nitric oxide synthase inhibition on tolerance to the analgesic action of D-Pen2,D-Pen5 enkephalin and morphine in the mouse. Neuropeptides 1996; 30:219-23
108. Zhao GM, Bhargava HN: Nitric oxide synthase inhibition attenuates tolerance to morphine but not to [D-Ala2,Glu4]deltorphin II, a -2-opioid receptor agonist in mice. Peptides 1996; 17:619-23
109. Bhargava HN, Cao YJ, Zhao GM: Effect of 7-nitroindazole on tolerance to morphine, U-50,488H and [D-Pen2,D-Pen5]enkephalin in mice. Peptides 1997; 18:797-800
110. Xu JY, Hill KP, Bidlack JM: The nitric oxide/cyclic GMP system at the supraspinal site is involved in the development of acute morphine antinociceptive tolerance. J Pharmacol Exp Ther 1998; 284:196-201
111. Santamarta MT, Ulibarri I, Pineda J: Inhibition of neuronal nitric oxide synthase attenuates the development of morphine tolerance in rats. Synapse 2005; 57:38-46
112. Herraez-Baranda LA, Carretero J, Gonzalez-Sarmiento R, Laorden ML, Milanes MV, Rodriguez RE: Evidence of involvement of the nNOS and the -opioid receptor in the same intracellular network of the rat periaqueductal gray that controls morphine tolerance and dependence. Brain Res Mol Brain Res 2005; 137:166-73
113. Abdel-Zaher AO, Hamdy MM, Aly SA, Abdel-Hady RH, Abdel-Rahman SRH: Attenuation of morphine tolerance and dependence by aminoguanidine in mice. Eur J Pharmacol 2006; 540:60-6
114. Bhargava HN, Kumar S, Barjavel MJ: Kinetic properties of nitric oxide synthase in cerebral cortex and cerebellum of morphine tolerant mice. Pharmacology 1998; 56:252-6
115. Lue WM, Su MT, Lin WB, Tao PL: The role of nitric oxide in the development of morphine tolerance in rat hippocampal slices. Eur J Pharmacol 1999; 383:129-35
116. Heinzen EL, Pollack GM: Pharmacodynamics of morphine-induced neuronal nitric oxide production and antinociceptive tolerance development. Brain Res 2004; 1023:175-84
117. Heinzen EL, Pollack GM: The development of morphine antinociceptive tolerance in nitric oxide synthase-deficient mice. Biochem Pharmacol 2004; 67:735-41
118. Heinzen EL, Booth RG, Pollack GM: Neuronal nitric oxide modulates morphine antinociceptive tolerance by enhancing constitutive activity of the -opioid receptor. Biochem Pharmacol 2005; 69:679-88
119. Leiper J, Vallance P: Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res 1999; 43:542-8
120. Kielstein A, Tsikas D, Galloway GP, Mendelson JE: Asymmetric dimethylarginine (ADMA)-a modulator of nociception in opiate tolerance and addiction? Nitric Oxide 2007; 17:55-9
121. Muscoli C, Cuzzocrea S, Ndengele MM, Mollace V, Porreca F, Fabrizi F, Esposito E, Masini E, Matsuschak GM, Salvemini D: Therapeutic manipulation of peroxynitrite attenuates the development of opoiate-induced antinociceptive tolerance in mice. J Clin Invest 2007; 117:3530-9
122. Bhargava HN: Attenuation of tolerance to, and physical dependence on, morphine in the rat by inhibition of nitric oxide synthase. Gen Pharmacol 1995; 26:1049-53
123. Dambisya YM, Lee TL: Role of nitric oxide in the induction and expression of morphine tolerance and dependence in mice. Br J Pharmacol 1996; 117:914-8
124. Rauhala P, Idanpaan-Heikkila JJ, Tuominen RK, Mannisto PT: N-nitro-Larginine attenuates development of tolerance to antinociceptive but not to hormonal effects of morphine. Eur J Pharmacol 1994; 259:57-64
125. Tsuchiya T, Takeuchi T, Hayashida K, Shimizu H, Ando K, Harada E: Milk-derived lactoferrin may block tolerance to morphine analgesia. Brain Res 2006; 1068:102-8
126. Dunbar S, Yaksh TL: Effect of spinal infusion of L-NAME, a nitric oxide synthase inhibitor, on spinal tolerance and dependence induced by chronic intrathecal morphine in the rat. Neurosci Lett 1996; 207:33-6
127. Powell KJ, Hosokawa A, Bell A, Sutak M, Milne B, Quirion R, Jhamandas K: Comparative effects of cyclo-oxygenase and nitric oxide synthase inhibition on the development and reversal of spinal opioid tolerance. Br J Pharmacol 1999; 127:631-44
128. Wong CS, Hsu MM, Chou YY, Tao PL, Tung CS: Morphine tolerance increases [3H]MK-904 binding affinity and constitutive neuronal nitric oxide synthase expression in rat spinal cord. Br J Anaesth 2000; 85:587-91
129. Cao JL, Ding HL, He JH, Zheng LC, Duan SM, Zeng YM: The spinal nitric oxide involved in the inhibitory effect of midazolam on morphine-induced analgesia tolerance. Pharmacol Biochem Behav 2005; 80:493-503
130. Liu W, Wang CH, Cui Y, Mo LQ, Zhi JL, Sun SN, Wang YL, Yu HM, Zhao CM, Feng JQ, Chen PX: Inhibition of neuronal nitric oxide synthase antagonizes morphine antinociceptive tolerance by decreasing activation of p38 MAPK in the spinal microglia. Neurosci Lett 2006; 410:174-7
131. Liang DY, Clark JD: Modulation of the NO/CO-cGMP signaling cascade during chronic morphine exposure in mice. Neurosci Lett 2004; 365:73-7
132. Xu T, Jiang W, Du D, Xu Y, Zhou Q, Pan X, Lou Y, Xu L, Ma K: Inhibition of MPEP on the development of morphine antinociceptive tolerance and the biosynthesis of neuronal nitric oxide synthase in rat spinal cord. Neurosci Lett 2008; 436:214-8
133. Wüster M, Schulz R, Herz A: Opioid tolerance and dependence. Trend Pharmacol Sci 1985; 6:64-7
134. Johnson SM, Fleming WW: Mechanisms of cellular adaptive sensitivity changes: applications to opioid tolerance and dependence. Pharmacol. Rev 1989; 41:435-88
135. Galea E, Regunathan S, Eliopoulos V, Feinstein DL, Reis DJ: Inhibition of mammalian nitric oxide synthases by agmatine, an endogenous polyamine formed by decarboxylation of arginine. Biochem J 1996; 316:247-9
136. Aricioglu F, Paul IA, Regunathan S: Agmatine reduces only peripheralrelated behavior signs, not the central signs, of morphine withdrawal in nNOS deficient transgenic mice. Neurosci Lett 2004; 354:153-7
137. Medvedev IO, Dravolina OA, Bespalov AY: Differential effects of nitric oxide synthase inhibitor, 7-nitroindazole, on discriminative stimulus and somatic effects of naloxone in morphine-dependent rats. Eur J Pharmacol 1999; 377:183-6
138. Afify EA, Daabees TT, Gabra BH, Abou Zeit-Har MS: Role of nitric oxide in catalepsy and hyperthermia in morphine-dependent rats. Pharmacol Res 2001; 44:533-9
139. Zarrindast MR, Homayoun H, Khavandgar S, Fayaz-Dastgerdi M, Fayaz- Dastgerdi M: The effects of simultaneous administration of -2-adrenergic agents with L-NAME or L-arginine on the development and expression of morphine dependence in mice. Behav Pharmacol 2002; 13:117-25
140. Zhou JF, Yan ZF, Ruan ZR, Peng FY, Cai D, Yuan H, Sun L, Ding DY, Xu SS: Heroin abuse and nitric oxide, oxidation, peroxidation, lipoperoxidation. Biomed Environ Sci 2000; 13:131-9
141. Kimes AS, Vaupel DB, London ED: Attenuation of some signs of opioid withdrawal by inhibitors of nitric oxide synthase. Psychopharmacology 1993; 112:521-4
142. Cappendijk SL, de Vries R, Dzoljic MR: Inhibitory effect of nitric oxide (NO) synthase inhibitors on naloxone-precipitated withdrawal syndrome in morphine- dependent mice. Neurosci Lett 1993; 162:97-100
143. Adams ML, Kalicki JM, Meyer ER, Cicero TJ: Inhibition of the morphine withdrawal syndrome by a nitric oxide synthase inhibitor, NG-nitro-L-arginine methyl ester. Life Sci 1993; 52:PL245-9
144. Thorat SN, Barjavel MJ, Matwyshyn GA, Bhargava HN: Comparative effects of NG-monomethyl-L-arginine and MK-801 on the abstinence syndrome in morphine-dependent mice. Brain Res 1994; 642:153-9
145. Cappendijk SL, Duval SY, de Vries R, Dzoljic MR: Comparative study of normotensive and hypertensive nitric oxide synthase inhibitors on morphine withdrawal syndrome in rats. Neurosci Lett 1995; 183:67-70
146. Vaupel DB, Kimes AS, London ED: Comparison of 7-nitroindazole with other nitric oxide synthase inhibitors as attenuators of opioid withdrawal. Psychopharmacology 1995; 118:361-8
147. Vaupel DB, Kimes AS, London ED: Nitric oxide synthase inhibitors. Preclinical studies of potential use for treatment of opioid withdrawal. Neuropsychopharmacology 1995; 13:315-22
148. Vaupel DB, Kimes AS, London ED: Further in vivo studies on attenuating morphine withdrawal: isoform-selective nitric oxide synthase inhibitors differ in efficacy. Eur J Pharmacol 1997; 324:11-20
149. Mori T, Ito S, Matsubayashi K, Sawaguchi T: Comparison of nitric oxide synthase inhibitors, phospholipase A2 inhibitor and free radical scavengers as attenuators of opioid withdrawal syndrome. Behav Pharmacol 2007; 18:725-9
150. Bhargava HN, Thorat SN: Evidence for a role of nitric oxide of the central nervous system in morphine abstinence syndrome. Pharmacology 1996; 52:86-91
151. Leza JC, Lizasoain I, Cuellar B, Moro MA, Lorenzo P: Correlation between brain nitric oxide synthase activity and opiate withdrawal. Naunyn Schmiedebergs Arch Pharmacol 1996; 353:349-54
152. Lizasoain I, Leza JC, Cuellar B, Moro MA, Lorenzo P: Inhibition of morphine withdrawal by lamotrigine: involvement of nitric oxide. Eur J Pharmacol 1996; 299:41-5
153. Bull PM, Ludwig M, Blackburn-Munro GJ, Delgado-Cohen H, Brown CH, Russell JA: The role of nitric oxide in morphine dependence and withdrawal excitation of rat oxytocin neurons. Eur J Neurosci 2003; 18:2545-51
154. Hall S, Milne B, Jhamandas K: Nitric oxide synthase inhibitors attenuate acute and chronic morphine withdrawal response in the rat locus coeruleus: an in vivo voltammetric study. Brain Res 1996; 739:182-91
155. Jhamandas JH, Harris KH, Petrov T, Jhamandas KH: Activation of nitric oxide-synthesizing neurons during precipitated morphine withdrawal. Neuroreport 1996; 7:2843-6
156. Sullivan ME, Hall SR, Milne B, Jhamandas K: Suppression of acute and chronic opioid withdrawal by a selective soluble guanylyl cyclase inhibitor. Brain Res 2000; 859:45-56
157. Pineda J, Torrecilla M, Martin-Ruiz R, Ugedo L: Attenuation of withdrawalinduced hyperactivity of locus coeruleus neurons by inhibitors of nitric oxide synthase in morphine-dependent rats. Neuropharmacology 1998; 37:759-67
158. Javelle N, Berod A, Renaud B, Lambas-Senas L: NO synthase inhibitors attenuate locus coeruleus catecholamine metabolism and behavior induced by morphine withdrawal. Neuroreport 2002; 13:725-8
159. Feng P, Meissler JJ, Adler MW, Eisenstein TK: Morphine withdrawal sensitizes mice to lipopolysaccharide: elevated TNF- and nitric oxide with decreased IL12. J Neuroimmunol 2005; 164:57-65
160. Buccafusco JJ, Terry AV, Shuster L: Spinal NMDA receptor-nitric oxide mediation of the expression of morphine withdrawal symptoms in the rat. Brain Res 1995; 679:189-99
161. Gao JL, Zeng YM, Zhang LC, Gu J, Liu HF, Zhou WH, Yang GD: NO mediated increase of Fos protein and NMDA1A R mRNA expression in rat spinal cord during morphine withdrawal. Acta Pharmacol Sin 2001; 22:505-11
162. Harlan RE, Webber DS, Garcia MM: Involvement of nitric oxide in morphine-induced c-Fos expression in the rat striatum. Brain Res Bull 2001; 54:207-12
163. Cao JL, Liu HL, Wang JK, Zeng YM: Cross talk between nitric oxide and ERK1/2 signaling pathway in the spinal cord mediates naloxone-precipitated withdrawal in morphine-dependent rats. Neuropharmacology 2006; 51:315-26
164. Chou WB, Zeng YM, Duan SM, Zhou WH, Gu J, Yang GD: M2 muscarinic receptor of spinal cord mediated increase of nNOS expression in locus coeruleus during morphine withdrawal. Acta Pharmacol Sin 2002; 23: 691-7